Jun 30, 2015
We return to the subject of personalized medicine and Pharmacogenomics - talking with Blake Toney, PharmD., MBA with Walgreens.
There’s been a series of genomic discoveries that tell us how individuals tolerate and metabolize a specific list of drugs flagged by the FDA. But physicians, for the most part, still aren’t applying this in practice. We have all this useful knowledge that would help patients, and it just gets ignored and as pharmacists who understand the science, it’s frustrating.
The science exists to screen people for a poor reaction to the drug, so it’s only administered to those who won’t get neuropathy – but it’s not being done, but why? We talk with Blake about the common objections and help set the record straight based on available data from the CDC, FDA, and the U.S. National Library of Medicine.
The Case for Personalized Medicine - Blake Toney PharmD MBA